Rhumbline Advisers boosted its holdings in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 6.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,076 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,080 shares during the period. Rhumbline Advisers owned 0.11% of Eagle Pharmaceuticals worth $1,018,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Municipal Employees Retirement System of Michigan increased its holdings in Eagle Pharmaceuticals by 6.7% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 1,910 shares of the specialty pharmaceutical company’s stock valued at $151,000 after purchasing an additional 120 shares in the last quarter. BNP Paribas Arbitrage SA increased its holdings in Eagle Pharmaceuticals by 58.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,456 shares of the specialty pharmaceutical company’s stock valued at $194,000 after purchasing an additional 908 shares in the last quarter. Bank of Montreal Can increased its holdings in Eagle Pharmaceuticals by 323.9% during the 2nd quarter. Bank of Montreal Can now owns 2,497 shares of the specialty pharmaceutical company’s stock valued at $197,000 after purchasing an additional 1,908 shares in the last quarter. Campbell Newman Asset Management Inc. increased its holdings in Eagle Pharmaceuticals by 4.9% during the 2nd quarter. Campbell Newman Asset Management Inc. now owns 2,693 shares of the specialty pharmaceutical company’s stock valued at $212,000 after purchasing an additional 126 shares in the last quarter. Finally, Foundry Partners LLC acquired a new stake in Eagle Pharmaceuticals during the 3rd quarter valued at $224,000.

A number of equities research analysts recently weighed in on EGRX shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $75.00 price target (down from $81.00) on shares of Eagle Pharmaceuticals in a report on Thursday, November 9th. Mizuho reaffirmed a “sell” rating and set a $37.00 price target on shares of Eagle Pharmaceuticals in a report on Wednesday, November 8th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $75.00 price target on shares of Eagle Pharmaceuticals in a report on Friday, October 27th. ValuEngine cut Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Finally, BidaskClub raised Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, December 2nd. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Eagle Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $62.33.

Shares of Eagle Pharmaceuticals, Inc. (NASDAQ EGRX) opened at $58.73 on Thursday. The company has a market capitalization of $890.52, a price-to-earnings ratio of 9.41 and a beta of 1.24. Eagle Pharmaceuticals, Inc. has a 52 week low of $45.05 and a 52 week high of $97.15. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.30 and a quick ratio of 5.15.

COPYRIGHT VIOLATION WARNING: “Eagle Pharmaceuticals, Inc. (EGRX) Position Raised by Rhumbline Advisers” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/12/14/eagle-pharmaceuticals-inc-egrx-position-raised-by-rhumbline-advisers.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.